Current therapeutic interventions in the glycation pathway: evidence from clinical studies
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The increased formation of advanced glycation endproducts ( AGEs ) constitutes a potential mechanism of hyperglycaemia‐induced micro‐ and macrovascular disease in diabetes. In vitro and animal experiments have shown that various interventions can inhibit formation and/or actions of AGEs , in particular the specific AGE inhibitor aminoguanidine and the AGEs crosslink breaker alagebrium, and the B vitamins pyridoxamine and thiamine, and the latter's synthetic derivative, benfotiamine. The potential clinical value of these interventions, however, remains to be established. The present review provides, from the clinical point of view, an overview of current evidence on interventions in the glycation pathway relating to (i) the clinical benefits of specific AGE inhibitors and AGE breakers and (ii) the potential AGE ‐inhibiting effects of therapies developed for purposes unrelated to the glycation pathway. We found that safety and/or efficacy in clinical studies with the specific AGE inhibitor, aminoguanidine and the AGE breaker, alagebrium, appeared to be a concern. The clinical evidence on the potential AGE ‐inhibiting effects of B vitamins is still limited. Finally, current evidence for AGE inhibition by therapies developed for purposes unrelated to glycation is limited due to a large heterogeneity in study designs and/or measurement techniques, which have often been sub‐optimal. We conclude that, clinical evidence on interventions to inhibit formation and/or action of AGEs is currently weak and unconvincing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873 · cited 14×
“In addition, no treatment effects on serum AGEs were found of anti-oxidant treatment with propionyl l-carnitine, sildenafil or both in individuals with T2DM and erectile dysfunction [164].”
BackgroundInfluentialDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Hammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785 · cited 2×
“probably due to maximizing transketolase activity, which stimulates the anaerobic pentose pathway of glycolysis and thereby reduces the level of glycolytic metabolites involved in the formation of AGEs [62].”
BackgroundNegre‐Salvayre, A., Coatrieux, C., Ingueneau, C., & Salvayre, R. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707395 · Cited by 641
Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes
Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., Zhu, L., Striker, G. E., & Vlassara, H. (2011) · Diabetes Care · doi:10.2337/dc11-0091 · Cited by 320 · cited 2×
“boiling, poaching, stewing or steaming food instead of frying, baking or grilling) were found to decrease serum CML and MG derivatives when compared to standard isocaloric diets in four studies in individuals with T1DM [150], T2DM [150,151] and in individuals on peritoneal dialysis [152] and healthy individuals [153].”
BackgroundResult
Cited by
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Self-citationBaking, Ageing, Diabetes: A Short History of the Maillard Reaction
Hellwig, M., & Henle, T. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308808 · Cited by 467
Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes
Heintz-Buschart, A., May, P., Laczny, C. C., Lebrun, L. A., Bellora, C., Krishna, A., Wampach, L., Schneider, J. G., Hogan, A., de Beaufort, C., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.180 · Cited by 316
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases
Maessen, D. E. M., Stehouwer, C. D. A., & Schalkwijk, C. G. (2015) · Clinical Science · doi:10.1042/cs20140683 · Cited by 334
Self-citationOxidative Stress in Health and Disease
Reddy, V. P. (2023) · Biomedicines · doi:10.3390/biomedicines11112925 · Cited by 333
Metadata
- Authors
- Engelen, L., Stehouwer, C. D. A., & Schalkwijk, C. G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-01-25
- Volume
- 15
- Issue
- 8
- Pages
- 677-689
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2011020502
- Cited by
- 122
- References
- 13
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current therapeutic interventions in the glycation pathway: evidence from clinical studies. https://app.cochat.ai/papers/10.1111/dom.12058
- The paper
- Engelen, L., Stehouwer, C. D. A., & Schalkwijk, C. G. (2013). Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.